DermaXon
Phase 1The company core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology.
Founded
2013
Focus
Small Molecules
About
The company core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology.
Funding History
2Total raised: $18.5M
Series A$15MUndisclosedNov 15, 2022
Seed$3.5MUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2013
LocationSan Diego, United States
StagePhase 1
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile